Gilead stock pops; experimental drug remdesivir is considered a front-runner in the race to develop a treatment for COVID-19 infections.
It’s hard to imagine a return to normalcy, but the time will come, when the world gets back to flying.
Record stimulus, unattractive investment alternatives like bonds, and a reconfiguration of supply chains might unleash a torrent of capital spending.
Many fear their companies won’t survive the pandemic, a survey of thousands of chief executives showed.